Wang Fengyan, Wang Mingdie, Chen Xiaoyan, Song Aiqi, Zeng Hui, Chen Jiawei, Wang Lingwei, Jiang Wanyi, Jiang Mei, Shi Weijuan, Li Yuqi, Zhong Heng, Chen Rongchang, Liang Zhenyu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, People's Republic of China.
Foshan Fourth People's Hospital, Foshan, 528000, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2025 May 31;20:1787-1795. doi: 10.2147/COPD.S510613. eCollection 2025.
Hospitalization due to chronic obstructive pulmonary disease (COPD) exacerbation is linked to worse prognosis and increased healthcare burden, especially in low- and middle-income countries. This study aimed to evaluate the quality of care and outcomes among inpatients with COPD and to identify prognostic factors relate to healthcare quality indicators.
A multi-center, retrospective longitudinal study was conducted. Patients hospitalized for COPD exacerbations between January and December 2017 were randomly sampled from 16 secondary or tertiary public general hospitals in China. Healthcare quality process indicators and clinical outcomes were collected from medical records and patient questionnaires. The median follow-up period was 666 days. Multivariate logistic regression analysis was used to identify risk factors for readmission or death within 30 days after discharge and for one-year mortality.
A total of 891 inpatients with COPD were included. Among them, 14.3% underwent post-bronchodilator spirometry. Documentation of exacerbation history and symptom scores was found in 16.8% and 1.2% of medical records, respectively. Long-acting bronchodilators (LABDs) were prescribed at discharge in 30.3% of cases. Verbal counseling was the primary approach to smoking cessation education, rather than the 5A method. The 30-day readmission rate was 7.1%. The average exacerbation rate was 0.94 per patient during the following year, and the one-year mortality rate was 7.2%. Prescription of inhaled LABDs at discharge was significantly associated with a lower risk of readmission or death within 30 days (HR 0.51, 95% CI 0.29-0.90, p=0.020). The presence of cardiovascular disease was associated with an increased risk of death within one year (HR 2.34, 95% CI 1.24-4.41, p=0.002).
The quality of inpatient care for COPD in China showed deficiencies in diagnostics, disease assessment, and patient education. Prescription of inhaled LABDs at discharge was a key quality measure that significantly reduced short-term readmission or mortality, highlighting its importance. Standardized protocols and clinician training are essential to improve patient outcomes.
慢性阻塞性肺疾病(COPD)急性加重导致的住院与更差的预后及增加的医疗负担相关,尤其是在低收入和中等收入国家。本研究旨在评估COPD住院患者的医疗质量和结局,并确定与医疗质量指标相关的预后因素。
进行了一项多中心回顾性纵向研究。从中国16家二级或三级公立综合医院中随机抽取2017年1月至12月因COPD急性加重住院的患者。从病历和患者问卷中收集医疗质量过程指标和临床结局。中位随访期为666天。采用多变量逻辑回归分析确定出院后30天内再入院或死亡以及一年死亡率的危险因素。
共纳入891例COPD住院患者。其中,14.3%的患者进行了支气管扩张剂后肺功能测定。分别有16.8%和1.2%的病历记录了急性加重病史和症状评分。30.3%的病例在出院时开具了长效支气管扩张剂(LABD)。言语咨询是戒烟教育的主要方式,而非5A法。30天再入院率为7.1%。次年每位患者的平均急性加重率为0.94次,一年死亡率为7.2%。出院时开具吸入性LABD与30天内再入院或死亡风险较低显著相关(HR 0.51,95%CI 0.29 - 0.90,p = 0.020)。心血管疾病的存在与一年内死亡风险增加相关(HR 2.34,95%CI 1.24 - 4.41,p = 0.002)。
中国COPD住院患者的医疗质量在诊断、疾病评估和患者教育方面存在不足。出院时开具吸入性LABD是一项关键的质量措施,可显著降低短期再入院率或死亡率,凸显了其重要性。标准化方案和临床医生培训对于改善患者结局至关重要。